NCT00918606已完成1 期
An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 主要终点
- Safety: Laboratory tests, medical exams
研究概览
简要总结
An Evaluation of the PK and Safety of LIPO-102 in Healthy Volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and non pregnant female
- •18-55 years old
- •Sufficient abdominal fat for injections
- •Signed informed consent
排除标准
- •Known hypersensitivity to study drugs
- •Treatment with an investigational agent within 30 days before first dose
研究组 & 干预措施
LIPO-102
Experimental
干预措施: LIPO-102 (Drug)
结局指标
主要结局
Safety: Laboratory tests, medical exams
时间窗: 4 weeks
次要结局
- Pharmacokinetics(24 hours)
研究者
相似试验
终止
1 期
Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.Atopic DermatitisNCT01447758LEO Pharma58
已完成
1 期
Evaluation of Safety and Pharmacodynamics of OP0201 Compared to Placebo in Healthy AdultsHealthy AdultsNCT03828149Novus Therapeutics, Inc17
已完成
1 期
Clinical Study of IBI362 in Healthy Chinese Male SubjectsOverweight/ObesityNCT04773977Innovent Biologics (Suzhou) Co. Ltd.24
已完成
1 期
A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01606371Eli Lilly and Company32
已完成
1 期
Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.Atopic DermatitisNCT06553287Lynk Pharmaceuticals Co., Ltd28